H. Lundbeck has agreed to buy privately owned Danish biotechnology firm Neuronicon to gain technologies for treating brain damage. Lundbeck, whose main products are anti-depressants and which hopes to grow in neurological treatments. The financial details were not disclosed. At the same time, Lundbeck signed a deal to cooperate with University of Arhus scientists on further neurology research over the next three years, the company said. NeuronIcon was founded by scientists at the University of Aarhus and is based on research conducted there and at the University of Berlin, Lundbeck said.